AR087863A1 - Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico - Google Patents

Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico

Info

Publication number
AR087863A1
AR087863A1 ARP120103377A ARP120103377A AR087863A1 AR 087863 A1 AR087863 A1 AR 087863A1 AR P120103377 A ARP120103377 A AR P120103377A AR P120103377 A ARP120103377 A AR P120103377A AR 087863 A1 AR087863 A1 AR 087863A1
Authority
AR
Argentina
Prior art keywords
combination
compound
peptidic
proteasome
formulate
Prior art date
Application number
ARP120103377A
Other languages
English (en)
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49549072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR087863(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of AR087863A1 publication Critical patent/AR087863A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Reivindicación 1: Un procedimiento para preparar una composición farmacéutica, en el que el procedimiento comprende: (i) proporcionar una primera combinación que comprende: (a) un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo; (b) una o más ciclodextrinas (CD); y (c) agua; en el que la una primera combinación es heterogénea y el compuesto o sal tiene una solubilidad baja en la primera combinación; y (ii) poner en contacto la primera combinación con un ácido para formar una segunda combinación, en la que el compuesto es más soluble en la segunda combinación que en la primera combinación. Reivindicación 24: Una composición farmacéutica preparada mediante el procedimiento de acuerdo con la reivindicación 1. Reivindicación 30: Un procedimiento para preparar una composición farmacéutica, en el que el procedimiento comprende: (i) proporcionar una primera combinación que comprende: (a) un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo; (b) SBECD; y (c) agua para inyectables; en el que la una primera combinación es heterogénea y el compuesto o sal tiene una solubilidad baja en la primera combinación; y (ii) poner en contacto la primera combinación con una solución acuosa de ácido cítrico para formar una segunda combinación, en la que el compuesto es más soluble en la segunda combinación que en la primera combinación.
ARP120103377A 2012-05-08 2012-09-13 Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico AR087863A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261644122P 2012-05-08 2012-05-08

Publications (1)

Publication Number Publication Date
AR087863A1 true AR087863A1 (es) 2014-04-23

Family

ID=49549072

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103377A AR087863A1 (es) 2012-05-08 2012-09-13 Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico

Country Status (21)

Country Link
US (2) US20130303482A1 (es)
JP (1) JP2015516416A (es)
KR (1) KR20150007361A (es)
CN (1) CN103781490A (es)
AR (1) AR087863A1 (es)
AU (1) AU2012238318B2 (es)
BR (1) BR112012028726B1 (es)
CA (1) CA2793894A1 (es)
CO (1) CO6571868A2 (es)
CR (1) CR20120485A (es)
CU (1) CU20120159A7 (es)
DO (1) DOP2012000252A (es)
EA (1) EA201201519A1 (es)
EC (1) ECSP12012167A (es)
MA (1) MA35238B1 (es)
MX (1) MX2012010891A (es)
MY (2) MY165002A (es)
SG (1) SG194417A1 (es)
TW (1) TWI603737B (es)
WO (1) WO2013169282A1 (es)
ZA (1) ZA201207384B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EP2814849B8 (en) 2012-02-15 2020-03-04 CyDex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
AU2014240122B2 (en) 2013-03-14 2019-02-14 Onyx Therapeutics, Inc. Dipeptide and tripeptide epoxy ketone protease inhibitors
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
AU2014290012B2 (en) 2013-07-19 2020-01-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
CN104945470B (zh) * 2014-03-30 2020-08-11 浙江大学 杂环构建的三肽环氧酮类化合物及制备和应用
CN103936828A (zh) * 2014-05-12 2014-07-23 苏州科耐尔医药科技有限公司 卡非佐米中间体及卡非佐米的制备方法
CN105919972A (zh) * 2015-12-18 2016-09-07 重庆两江药物研发中心有限公司 一种包载卡非佐米的纳米粒制剂及其制备方法
TWI759301B (zh) * 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
BR112019002191A2 (pt) 2016-08-05 2019-05-21 Amgen Inc. síntese de (s)-2-amino-4-metil-1-((r)-2-metiloxirana-2-il)-pentan-1-ona e sal farmaceuticamente aceitável do mesmo
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
WO2018183686A1 (en) * 2017-03-31 2018-10-04 Valent Biosciences Llc 1-aminocyclopropane-1-carboxylic acid polymorphs
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
US11241502B2 (en) 2017-11-16 2022-02-08 Amgen Inc. Stable compositions of pegylated carfilzomib compounds
CN111683654A (zh) * 2017-11-30 2020-09-18 细胞凝胶制药有限责任公司 新型镇痛药物制剂及其用途
WO2021257941A1 (en) * 2020-06-19 2021-12-23 Amgen Inc. Methods of measuring carfilzomib
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19
CN113406183A (zh) * 2021-06-29 2021-09-17 宁波大学 基于离子淌度质谱仪高效识别青霉胺手性对映体的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005026556D1 (de) * 2004-12-07 2011-04-07 Proteolix Inc Zusammensetzung zur proteasomhemmung
NZ595196A (en) * 2005-11-09 2013-03-28 Proteolix Inc Peptide-based compounds for enzyme inhibition
EP2207791B2 (en) * 2007-10-04 2019-08-07 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides

Also Published As

Publication number Publication date
CU20120159A7 (es) 2014-03-26
MX2012010891A (es) 2014-03-05
WO2013169282A1 (en) 2013-11-14
SG194417A1 (en) 2013-12-30
TW201345543A (zh) 2013-11-16
JP2015516416A (ja) 2015-06-11
AU2012238318B2 (en) 2014-02-13
AU2012238318A1 (en) 2013-11-28
CA2793894A1 (en) 2013-11-08
ECSP12012167A (es) 2013-02-28
MA35238B1 (fr) 2014-07-03
KR20150007361A (ko) 2015-01-21
BR112012028726B1 (pt) 2021-07-13
CR20120485A (es) 2013-12-18
EA201201519A1 (ru) 2013-11-29
NZ602490A (en) 2016-03-31
US20130303465A1 (en) 2013-11-14
TWI603737B (zh) 2017-11-01
MY165002A (en) 2018-02-28
CN103781490A (zh) 2014-05-07
BR112012028726A2 (pt) 2016-07-19
CO6571868A2 (es) 2012-11-30
US20130303482A1 (en) 2013-11-14
MY196510A (en) 2023-04-18
ZA201207384B (en) 2018-12-19
DOP2012000252A (es) 2013-12-31

Similar Documents

Publication Publication Date Title
AR087863A1 (es) Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico
NI201200017A (es) Formulación farmacéutica
NZ628398A (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
AR085668A1 (es) Terapias combinadas para malignidades hematologicas
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
ECSP14013239A (es) Composiciones farmacéuticas
AR085155A1 (es) Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
BR112012026338A2 (pt) novos derivados de 3,3-dimetil tetrahidroquinolina
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
MX2019004845A (es) Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
DK1948133T3 (da) Argatrobanpræparat indeholdende en syre som opløselighedsfremmende middel
BR112014006248A2 (pt) compostos de triazolopiridina como inibidores de pde10a
CR20140053A (es) Formulaciones de ácido desoxicólico y sales del mismo
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
CL2012003488A1 (es) Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.
PE20130374A1 (es) Composicion farmaceutica que comprende ibuprofeno
EA201490573A1 (ru) Соединение бензотиазолона
ES2478447T3 (es) Formulaciones del ácido desoxicólico y sus sales
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
CY1122598T1 (el) Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης
AR092627A1 (es) Derivados glucopiranosidos de urea
AR082022A1 (es) Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal

Legal Events

Date Code Title Description
FC Refusal